Oncolytics Biotech Inc T.ONC

Antibody-drug conjugates (ADCs) company CCO departs

[Noteable]

Nov 01, 2022 - WALTHAM, Mass.-- ImmunoGen, Inc. , involved in the field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Kristen Harrington-Smith, Senior Vice President and Chief Commercial Officer (CCO), will be departing the Company. 

https://www.biospace.com/article/releases/immunogen-announces-departure-of-chief-commercial-officer-november-01-2022/

[Noteable]

ADCs encounter major obstacles including, low blood residency time, low penetration capacity to tumor microenvironment, low payload potency, immunogenicity, unusual off-target toxicity, drug resistance, and the lack of stable linkage in blood circulation. That said (ADCs) are an emerging therapeutic modality for targeted cancer treatment that represent the amalgamation of chemotherapy and

[Noteable]

Another unexpected challenge faced by many ADC developers during clinical evaluations is the inability of ADCs to demonstrate benefit compared to controls, such as MM-302. MM-302 is an anti-HER2 monoclonal antibody conjugated to doxorubicin.

[Noteable]

The Phase II HERMIONE trial (NCT02213744) which involved MM-302, the anti-HER2 monoclonal antibody conjugated to doxorubicin, was discontinued due to a lack of benefit from a placebo treatment.   Another ADC that reported a similar situation was Rovalpitumab tesirine (RovA-T), encouraging results from the Phase I trial reported 18% ORR in assessable patients, 38% ORR in

[m00nsh0ts]

Gives rise to the question of why Gilead paid so much for Immunomedics?

[Noteable]

Gilead paid up US$ 21 Billion for Immunomedics hydolysable linker that is the major part of their ADC technology which delivers chemotherapy metabolites to the cancer tumor site and their tumor microenvironments. This hydrolysable linker permits intracellular and extracellular release of a membrance permeable payload that claims to activate the "bystander effect" in the TME along with

[Noteable]

Of note ... ONCY's pelareorep is targeting the HR+/HER2 negative breast cancer segment in contrast to the TROP-2 ADCs which are targeting the HR+/HER2 positive/low segment.

[Noteable]

October 31, 2022 - Daiichi Sankyo sets new highs for AstraZeneca-partnered ADC cancer drug Enhertu The Japanese pharma on Monday upped its forecast for Enhertu this year by more than $400 million, projecting it could haul in about $1.3 billion in sales this year. Daiichi recently noted that Enhertu hit on a primary endpoint for a Phase III postmarket commitment trial after winning